Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
02 October 2019 - 9:05PM
Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage
biopharmaceutical company focused on developing curative cell
therapies for cancer, today announced acceptance of a presentation
at the 34th annual meeting of the Society for Immunotherapy of
Cancer (SITC) being held November 6–10, 2019 in National Harbor,
Maryland.
“Our BOXR platform aims to discover novel transgenes
co-expressed with chimeric-targeting receptors to improve T cell
functionality in the solid tumor microenvironment,” said Seth
Ettenberg, Ph.D., Chief Scientific Officer of Unum. “At this year’s
SITC meeting, we are pleased to present preclinical data from
BOXR1030, our first product candidate from this platform, and the
role of the addition of the GOT2 transgene to the BOXR1030
construct that was discovered as part of this effort.”
Unum’s poster presentation at SITC:
Title: Co-expression of the Metabolic
Enzyme GOT2 with a GPC3-Targeted CAR-T Overcomes Challenges of the
Solid Tumor Microenvironment, Substantially Improving Therapeutic
Efficacy in Solid Tumor Xenografts (Abstract #P227)Date: Friday
November 8, 2019
About Unum Therapeutics
Unum Therapeutics is a clinical-stage
biopharmaceutical company focused on developing curative cell
therapies to treat a broad range of cancer patients. Unum’s novel
proprietary technologies include Antibody-Coupled T cell Receptor
(ACTR), an autologous engineered T-cell therapy that combines the
cell-killing ability of T cells and the tumor-targeting ability of
co-administered antibodies to exert potent antitumor immune
responses, and Bolt-On Chimeric Receptor (BOXR), designed to
improve the functionality of engineered T cells by incorporating a
“bolt-on” transgene to overcome resistance of the solid tumor
microenvironment to T cell attack. Unum has multiple programs in
Phase 1 clinical testing, including ACTR707 used in combination
with rituximab in adult patients with r/r NHL and used in
combination with trastuzumab in adult patients with HER2+ advanced
cancer, and ACTR087 used in combination with the novel antibody
SEA-BCMA in r/r multiple myeloma. Unum’s BOXR1030 program targeting
GPC3, an oncofetal antigen expressed in a variety of tumors
including certain liver and lung cancers, is the first product
candidate from the BOXR platform with preclinical studies underway
to support the filing of an investigational new drug (IND)
application. The Company is headquartered in Cambridge, MA.
Follow Unum Therapeutics on social media:
@UnumRx, and LinkedIn.
Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
Media Contact:
Lissette Steele, 202-930-4762
lsteele@vergescientific.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From May 2023 to May 2024